Non-Muscle Invasive Bladder Cancer VL

Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos

Details
John Sfakianos and Amir Horowitz join Ashish Kamat discussing a novel immune checkpoint axis in non-muscle-invasive bladder cancer, specifically looking at the HLA-E and NKG2A axis in non-muscle invasive bladder cancer, as it relates to Bacillus Calmette-Guerin (BCG) and BCG resistance. Biographies: Amir Horowitz, Ph.D., is an Assistant Professor of Oncological Sciences and a member of the Precisi...

Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li

Details
Joining Dr. Ashish Kamat from the Moffit Cancer Center in Tampa, Florida is Dr. Roger Li to dive into all things BCG unresponsive bladder cancer. Dr. Li shares what is known about BCG unresponsive disease, some of the conundrums that clinicians and the FDA are challenged by when evaluating and designing clinical trials in this area, and answers a series of questions from Dr. Kamat covering many to...

The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker

Details
Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the det...

Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk

Details
Siamak Daneshmand and Marek Babjuk join Ashish Kamat in this conversation on improving tumor detection through improved visibility and reducing recurrence rates of bladder cancer. Siamak Daneshmand offers his perspective on the use of Blue Light Cystoscopy (BLC®) with Cysview® for improving detection and reduced recurrence of bladder cancer. Marek Babjuk presents his perspective on the use of phot...

Trained Immunity as a Molecular Mechanism for BCG Immunotherapy - Sita Vermeulen

Details
In this conversation with Ashish Kamat, Sita Vermeulen details a perspective recently published in Nature Reviews Urology on trained immunity as a molecular mechanism for Bacillus Calmette-Guerin or BCG immunotherapy in bladder cancer. BCG is the gold standard adjuvant therapy for high-risk nonmuscle-invasive bladder cancer (NMIBC). One of the aspects of innate immunity that has not been a topic o...

Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni

Details
The Phase 3 data from the United States clinical trial evaluating an investigational gene therapy, nadofaragene firadenovec (rAd-IFN/Syn3), for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) was recently published in The Lancet Oncology. In this conversation with Dr. Ashish Kamat, Girish Kulkarni, MD discusses the k...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...

High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi

Details
Bacillus Calmette-Guerin (BCG) has been the standard of care for patients with non muscle-invasive bladder cancer for decades. However, within five years of the first instillation of BCG therapy, about 50% of tumors recur, and 20% of tumors will progress. To overcome BCG resistance, we need to understand the mechanisms of a BCG therapeutic effect and identify molecular correlates that can predict...

Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay

Details
Justin Matulay, MD, joins Ashish Kamat, MD, MBBS, to review his work assessing the variability in guideline management and adherence for non-muscle Invasive Bladder Cancer (NMIBC) among members of the Society for Urologic Oncology (SUO). As bladder cancer poses a significant risk to the population and most diagnoses are non-muscle invasive, Dr. Matulay and colleagues at MD Anderson Cancer Center w...

Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney

Details
Ashish Kamat is joined by Colin Dinney to discuss the results of the SUO-CTC Phase 3 Trial of nadofaragene firadenovec for patients with non-muscle invasive bladder cancer unresponsive to BCG. Dr. Dinney presents slides and discusses how most NMIBC patients recur despite BCG therapy, and there is an unmet need for therapies in patients' refractory to BCG. Previously, Nadofaragene firadenovec was t...